Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu Vaccine Allotment Plan Prioritizes States With Chiron Contracts

This article was originally published in The Pink Sheet Daily

Executive Summary

All states should receive at least half of their contracted influenza vaccine supply in the first phase of Sanofi-Aventis’ Fluzone dose distribution in cooperation with the CDC. Other “first phase” recipients will include the Vaccines for Children program, pediatricians with Aventis contracts.

You may also be interested in...



FDA Fluvirin Inspections Focusing On Readiness For 2005

"Ongoing FDA investigation" is looking at "manufacturing quality systems related to assuring sterility of final vaccine product," agency says. Pledge to cooperate with British authorities may signal truce on regulatory finger pointing.

FDA Fluvirin Inspections Focusing On Readiness For 2005

"Ongoing FDA investigation" is looking at "manufacturing quality systems related to assuring sterility of final vaccine product," agency says. Pledge to cooperate with British authorities may signal truce on regulatory finger pointing.

Sanofi-Aventis To Ship 55.4 Mil. Fluzone Doses For 2004-05 Flu Season

The Centers for Disease Control & Prevention is requesting that the influenza vaccine go to "high-risk" individuals. FDA scientists will tour Chiron's Liverpool manufacturing facility Oct. 9-10 following the U.K.'s decision to suspend the release of Fluvirin for three months.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel